Approximately one-third of patients with metastatic triple-negative breast cancer (TNBC) develop brain metastases during their lifetime. Notably, up to 90% of TNBC brain metastases express B7-H3, a molecule that contributes to an immunosuppressive mic…
Background
CD47 functions as a “don’t eat me” checkpoint, inhibiting macrophage-mediated phagocytosis in triple-negative breast cancer (TNBC). While anti-CD47 therapies can restore immune surveillance, their efficacy in TNBC is often limited by …
Background
Glucose restriction is a hallmark of the tumor microenvironment (TME), yet how tumor cells adapt to this metabolic stress and the impact of metabolic reprogramming on the TME remains incompletely understood.
Methods
A genome-wide CRISPR kn…
A recent study by Grippin et al showed that COVID-19 mRNA-lipid nanoparticle vaccines can be strategically implemented to fundamentally reshape the immunosuppressive tumor microenvironment and boost the efficacy of immune checkpoint inhibitors (ICIs) …
Background
While chimeric antigen receptor (CAR) T cells have achieved encouraging remission rates in hematological malignancies, they have demonstrated limited success in treating glioblastoma (GBM), particularly due to high intratumoral and intertum…
Natural killer (NK) cells are critical effectors of antitumor immunity, however their cytotoxic function is frequently impaired within the tumor microenvironment (TME). Tumor-associated macrophages (TAMs), the most abundant immune stromal population i…
Background
The immunologically “cold” microenvironment of triple-negative breast cancer presents a major obstacle to treatment, conferring resistance to current immunotherapies. Targeting the stimulator of interferon genes (STING) pathway has emerged …
Background
High-grade serous carcinoma (HGSC) of the ovary acquires chemoresistance through diverse cancer cell-intrinsic and cell-extrinsic mechanisms, culminating in treatment-refractory intraperitoneal metastasis. Previous work suggests that chemot…
Background
Tumor-infiltrating lymphocytes (TILs) are established determinants of clinical outcomes in breast cancer.1–6 While stromal TILs (sTILs) are commonly evaluated due to easier scoring and higher interobserver reproducibility, intraepithe…
